Ranibizumab biosimilar (Hangzhou Zhongmei Huadong)

雷珠单抗生物类似药（杭州中美华东）

Report date: 2025/05/30 13:59:27

Base Information

Drug NameRanibizumab biosimilar (Hangzhou Zhongmei Huadong)
Drug Alias NameRimmyrahHJY-28HJY28
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody fragment > Fab fragmentBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVascular endothelial growth factor A inhibitors
TargetsVascular endothelial growth factor A
Therapy Area/IndicationsWet age-related macular degenerationMacular Degeneration
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesHangzhou Jiuyuan Gene Biomedical Co LtdHangzhou Zhongmei Huadong Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsWet age-related macular degenerationMacular Degeneration
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A